Patents by Inventor Daniel W. Kulp

Daniel W. Kulp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240207385
    Abstract: The disclosure generally relates to compositions comprising self-assembling vaccines and methods of using the same. The disclosure provides compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence encoding a self-assembling polypeptide or a pharmaceutically acceptable salt thereof and a second nucleic acid sequence encoding a viral antigen or a pharmaceutically acceptable salt thereof. The disclosure further provides compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence encoding a self-assembling polypeptide or a pharmaceutically acceptable salt thereof and a second nucleic acid sequence encoding a CD40 ligand polypeptide. Methods of using any of the disclosed compositions are also provided.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 27, 2024
    Inventors: Daniel W. KULP, David B. WEINER, Ziyang XU, Kar MUTHUMANI
  • Publication number: 20230285549
    Abstract: Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a sequence that encodes an adjuvant polypeptide or a pharmaceutically acceptable salt thereof and a second nucleic acid sequence comprising a sequence that encodes an antigen from a virus or from a cancer. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker.
    Type: Application
    Filed: June 30, 2021
    Publication date: September 14, 2023
    Applicant: THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY
    Inventors: Ziyang XU, Daniel W. KULP, David B. WEINER
  • Publication number: 20230149535
    Abstract: Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a sequence that encodes a self-assembling polypeptide or a pharmaceutically acceptable salt thereof and a second nucleic acid sequence comprising a sequence that encodes an antigen from a virus from the family of Coronaviridae. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker.
    Type: Application
    Filed: April 12, 2021
    Publication date: May 18, 2023
    Inventors: Daniel W. KULP, David B. WEINER, Yuanhan WU
  • Publication number: 20220370591
    Abstract: Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a leader sequence or a pharmaceutically acceptable salt thereof; and a second nucleic acid sequence comprising a sequence that encodes a trimer of a retroviral envelope or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker. Also disclosed are pharmaceutical compositions comprising these compositions and methods of using the disclosed compositions.
    Type: Application
    Filed: April 6, 2020
    Publication date: November 24, 2022
    Inventors: Megan WISE, Daniel W. KULP, David B. WEINER
  • Publication number: 20220047695
    Abstract: Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a leader sequence or a pharmaceutically acceptable salt thereof; and a second nucleic acid sequence comprising a sequence that encodes a self-assembling polypeptide or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker. Also disclosed are pharmaceutical compositions comprising these compositions and methods of using the disclosed compositions.
    Type: Application
    Filed: December 23, 2019
    Publication date: February 17, 2022
    Inventors: Ziyang Xu, Daniel W. Kulp, David B. Weiner
  • Publication number: 20210363194
    Abstract: The present invention relates to glycosylate HIV timer nanoparticles fused to self-assembling ferritin proteins which may be utilized as immunogens to enhance trafficking to lymph nodes and germinal centers and to heighten immune responses.
    Type: Application
    Filed: June 5, 2019
    Publication date: November 25, 2021
    Inventors: Talar Tokatlian, Benjamin J. Read, Daniel W. Kulp, Sergey Menis, Jon M. Steichen, William R. Schief, Darrell J. Irvine
  • Patent number: 9707290
    Abstract: The present application relates to immunogens of broadly neutralizing monoclonal antibodies specific for HIV-1, such as broad and potent neutralizing monoclonal antibodies specific for HIV-1 and their gernation and methods of use. Broad neutralization suggests that the antibodies can neutralize HIV-1 isolates from different individuals. Immunogens or vaccines which may elicit such antibody associated responses are useful in pharmaceutical compositions for the prevention and treatment of HIV, and for the diagnosis and monitoring of HIV infection.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: July 18, 2017
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: William R. Schief, Bruno E. Correia, Daniel W. Kulp, Ron Jacak
  • Publication number: 20150238594
    Abstract: The present application relates to immunogens of broadly neutralizing monoclonal antibodies specific for HIV-1, such as broad and potent neutralizing monoclonal antibodies specific for HIV-1 and their gernation and methods of use. Broad neutralization suggests that the antibodies can neutralize HIV-1 isolates from different individuals. Immunogens or vaccines which may elicit such antibody associated responses are useful in pharmaceutical compositions for the prevention and treatment of HIV, and for the diagnosis and monitoring of HIV infection.
    Type: Application
    Filed: March 10, 2015
    Publication date: August 27, 2015
    Inventors: William R. Schief, Bruno E. Correia, Daniel W. Kulp, Ron Jacak